Cohort Imbalance
Unrecognized vascular-risk differences may create meaningful imbalance across treatment arms or trial subgroups.
Clinical development decision support
Calculate hidden vascular-risk differences before they affect your trial design.
PhaseVantage helps Phase 2 and Phase 3 cancer trial teams understand how macrovascular invasion may affect cohort balance, endpoint interpretation, and development confidence.
Radiologist-led analysis. AI-supported review. Trial-ready recommendations.
Hidden risk made visible
Standard Trial View
Arm A
Arm B
Standard cohort view: Risk differences are based only on demographics.
PhaseVantage Analysis
- CT imaging
- Radiologist review
- AI-supported MVI assessment
Restratified MVI Risk View
Arm A
Arm B
LowModerateHigh
MVI risk imbalance identified: Potential impact on endpoint interpretation, subgroup analysis, and Phase 2/3 outcomes.
The trial interpretation problem
Hidden vascular-risk differences can weaken trial signal.
Patients with pancreatic adenocarcinoma may have very different macrovascular invasion profiles, even within the same trial population. If those differences are not understood, treatment effects may appear weaker, endpoints may be harder to interpret, and trial outcomes may not be as clear.
Macrovascular invasion is not only an imaging issue. It is a trial interpretation and development-risk issue.
Endpoint Uncertainty
Macrovascular invasion influences how progression, treatment outcomes, response, and survival should be interpreted.
Development Risk
If vascular-risk effects are not accounted for sponsors may make costly decisions during trial design that may ultimately lead to misinterpretation or trial failure.
PhaseVantage approach
A clearer vantage point on trial risk.
PhaseVantage combines expert pancreatic CT review with machine learning models trained on real pancreatic adenocarcinoma CTs to identify macrovascular invasion patterns and translate them into actionable trial recommendations. These recommendations help sponsors maximize the likelihood of successful trial outcomes.
Expert CT Review
Radiologists assess tumor-vessel involvement and clinically meaningful macrovascular invasion patterns.
AI-Supported Analysis
Machine learning tools support consistent vascular-risk assessment across pancreatic adenocarcinoma CT imaging.
Trial-Ready Recommendations
Sponsors receive concrete findings that can inform analysis, stratification, cohort interpretation, and trial design.
Core service
A focused advisory service for Phase 2 and Phase 3 teams.
PhaseVantage MVI Trial Impact Assessment
We meet with trial sponsors, review available CT imaging and trial context, analyze macrovascular invasion risk, and deliver a clear report explaining how vascular invasion may affect clinical trial outcomes.
This service is designed for teams that need to understand whether hidden vascular-risk differences are influencing cohort balance, treatment response, endpoint interpretation, or Phase 2 to Phase 3 decision-making.
Inputs
- Pancreatic adenocarcinoma CT imaging
- Trial design context
- Cohort and endpoint information
- Sponsor decision questions
Analysis
- Expert radiology review
- AI-supported MVI assessment
- Cohort-level risk interpretation
- Trial impact analysis
Outputs
- MVI risk summary
- Cohort balance interpretation
- Subgroup recommendations
- Sponsor-ready action report
Trial DataMVI Risk AnalysisRecommendations
Engagement workflow
From CT imaging to trial decisions.
- 1
Discovery Call
We clarify the trial question, phase, endpoint concerns, available imaging, and sponsor decision needs.
- 2
Data Review
We review CT imaging, trial design information, and relevant cohort details.
- 3
MVI Analysis
Radiologists and AI tools assess macrovascular invasion risk across the patient cohort.
- 4
Trial Impact Interpretation
We identify how MVI risk may affect cohort balance, treatment response, endpoint interpretation, or subgroup effects.
- 5
Actionable Report
We deliver practical recommendations for current analysis, future trial design, or sponsor decision-making.
PhaseVantage Impact Report
| Arm | Low | Moderate | High |
|---|---|---|---|
| A | 42% | 35% | 23% |
| B | 30% | 38% | 32% |
Recommendation: evaluate MVI risk as an explanatory covariate for endpoint interpretation.
Sponsor deliverables
Clear outputs your development team can use.
PhaseVantage delivers more than a radiology readout. We provide a decision-support report for clinical development teams.
- Patient-level macrovascular invasion risk summary
- Cohort-level MVI risk distribution
- Treatment-arm balance interpretation
- Endpoint and subgroup-analysis recommendations
- Trial-design adjustment recommendations
- Executive summary for sponsor leadership
Sponsor value
Improve confidence before major trial decisions.
Reveal Hidden Risk
Identify vascular-risk differences that may not be visible from standard trial grouping alone.
Improve Interpretation
Better understand heterogeneous treatment response across pancreatic cancer trial populations.
Support Better Analysis
Use MVI risk as a potential subgroup, covariate, or explanatory variable.
Inform Future Design
Refine eligibility, stratification, endpoint strategy, or follow-on trial design.
Reduce Uncertainty
Give clinical development teams more confidence before major go/no-go decisions.
Who it is for
Built for pancreatic cancer clinical development teams.
Clinical Development Leaders
For leaders who need better evidence before making costly program decisions.
Phase 2 and Phase 3 Trial Teams
For teams designing, reviewing, or interpreting pancreatic adenocarcinoma studies.
Translational Medicine Teams
For teams connecting imaging-derived risk features to disease biology and treatment response.
Imaging Core Lab Partners
For imaging teams seeking deeper macrovascular invasion interpretation.
Biostatistics and Evidence Teams
For teams evaluating subgroup effects, covariates, cohort balance, and exploratory analyses.
Expert team
Meet the experts behind PhaseVantage.
Our team brings together pancreatic cancer imaging expertise, radiology review, machine learning, clinical trial strategy, and data-driven decision support.
Dr. Kirk Gasper, Ph.D.
CEO, informatics lead, co-founderDr. Kirk Gasper is a biomedical informatics scientist focused on cancer biology, pancreatic cancer progression, and clinically meaningful patient outcomes. He earned his Ph.D. from the University of Nebraska at Omaha, working with Dr. Dario Ghersi and Dr. Matteo Ligorio. His research supports ongoing efforts to characterize the spatial biology of pancreatic ductal adenocarcinoma, including the role of macrovascular infiltration in cancer progression.
Dr. Matteo Ligorio, M.D.
Surgical lead, macrovascular invasion lead, co-founderDr. Matteo Ligorio is a physician-scientist with expertise in pancreatic cancer biology, clinical research, and translational oncology. He earned his M.D. from the University of Genoa and a Ph.D. in molecular epidemiology and biostatistics from Harvard Medical School, with subsequent appointments at Harvard, Massachusetts General Hospital, and UT Southwestern. His research has advanced understanding of pancreatic tumor behavior, patient survival predictors, and novel therapeutic delivery approaches, with publications in journals including Nature and Cell.
Dr. Dario Ghersi, M.D., Ph.D.
Computational biology and AI lead, co-founderDr. Dario Ghersi is a biomedical informatics and computational biology expert with training in medicine, structural bioinformatics, cancer genomics, and machine intelligence. He earned his M.D. from the University of Genoa and his Ph.D. in Computational Biology from Mount Sinai School of Medicine, followed by postdoctoral work at Princeton University on large-scale genome sequencing data. His research spans cancer genomics, immunoinformatics, structural bioinformatics, and AI-driven biomedical analysis.
Dr. Matt Hale, Ph.D.
Enterprise software architect, cybersecurity lead, co-founderDr. Matt Hale is an Associate Professor of Cybersecurity at the University of Nebraska at Omaha, Director of the Nebraska University Center for Cybersecurity, and founder of MATRIX, an AI-enabled cybersecurity workforce and operations initiative. His research sits at the intersection of cybersecurity, software engineering, and human-centered computing. Dr. Hale received his Ph.D. from the University of Tulsa, where he worked with the Air Force Office of Scientific Research on formal certification tools for information assurance in cloud-based information systems.
Confidential consultation
Get a clearer view of your pancreatic cancer trial risk.
Request a confidential consultation to discuss how PhaseVantage can help your team understand whether macrovascular invasion is affecting trial interpretation, cohort balance, or Phase 2 to Phase 3 decision-making.
We work with sponsor teams under appropriate confidentiality, data-use, and compliance agreements.